Relay Therapeutics to advance Zovegalisib to Phase 3 breast cancer trial
Relay Therapeutics (NASDAQ:RLAY) announced on Monday that it will advance its lead candidate, zovegalisib, into a planned Phase 3 frontline trial for the treatment of PIK3CA-mutated, HR+/HER2- metastatic breast cancer.
The company aims to initiate the pivotal study in early 2027, pending final regulatory feedback.
The decision is supported by new clinical data showing a 44% objective response rate (ORR) among 34 measurable patients in a median third-line setting.
The data highlights the drug's potential efficacy in a population that has already undergone multiple prior therapies.
Safety profiles indicated a 3% discontinuation rate for zovegalisib, though the study noted a 40% rate of Grade 3 or higher treatment-related adverse events (TRAEs).
The upcoming Phase 3 trial will utilize a combination therapy approach.
Under a supply agreement, Pfizer will provide atirmociclib to be used alongside zovegalisib.
Relay also disclosed a pharmacokinetic interaction that increases zovegalisib exposure approximately 2.5-fold, a factor that will likely inform dosing strategies in the upcoming late-stage study.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
